BIOPIX-T

Pre-clinical

Grenoble, Europe - OtherFounded 2019biopix-t.com

Founded in 2019 as a spin-off from IMBB-FORTH, BIOPIX-T is building a diagnostics ecosystem centered on its proprietary, 3D-printed Pebble device, which performs real-time quantitative colorimetric LAMP (qcLAMP) assays. The company has achieved CE-IVD certification for its platform and associated test kits, targeting the infectious disease diagnostics market with a focus on accessibility and ease of use. Backed by venture capital and angel investors, BIOPIX-T is led by a team of scientists and professionals aiming to expand its product portfolio and global presence.

Founded

2019

Focus

Diagnostics

AI Company Overview

Technology Platform

The Pebble qcLAMP Platform: a portable, 3D-printed device using real-time quantitative colorimetric Loop-Mediated Isothermal Amplification (qcLAMP) for rapid, smartphone-controlled molecular diagnostics at the point of care.

Opportunities

Significant growth opportunity lies in expanding the test menu for the Pebble platform into new infectious diseases and high-value companion diagnostics.

The development of the 'PixL' device targets the large and growing consumer/home testing market, representing a major expansion avenue.

Risk Factors

Key risks include intense competition from large, established diagnostics companies, challenges in achieving widespread market adoption and reimbursement, and execution risk in scaling manufacturing and delivering a robust pipeline of new assays.

Competitive Landscape

Competes against large molecular diagnostics firms (e.g., Cepheid, Abbott) and lateral flow test manufacturers. Differentiation is based on the Pebble platform's unique combination of low cost, portability, quantitative results, and smartphone integration for decentralized testing.